{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:12:39Z","timestamp":1790259159560,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Orexin neuropeptides regulate sleep\/wake through orexin receptors (OX\n                    <jats:sub>1<\/jats:sub>\n                    R, OX\n                    <jats:sub>2<\/jats:sub>\n                    R); OX\n                    <jats:sub>2<\/jats:sub>\n                    R is the predominant mediator of arousal promotion. The potential for single OX\n                    <jats:sub>2<\/jats:sub>\n                    R antagonism to effectively promote sleep has yet to be demonstrated in humans. MK-1064 is an OX\n                    <jats:sub>2<\/jats:sub>\n                    R-single antagonist. Preclinically, MK-1064 promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats at OX\n                    <jats:sub>2<\/jats:sub>\n                    R occupancies higher than the range observed for dual orexin receptor antagonists. Similar to dual antagonists, MK-1064 increases NREM and REM sleep in dogs without inducing cataplexy. Two Phase I studies in healthy human subjects evaluated safety, tolerability, pharmacokinetics and sleep-promoting effects of MK-1064, and demonstrated dose-dependent increases in subjective somnolence (via Karolinska Sleepiness Scale and Visual Analogue Scale measures) and sleep (via polysomnography), including increased REM and NREM sleep. Thus, selective OX\n                    <jats:sub>2<\/jats:sub>\n                    R antagonism is sufficient to promote REM and NREM sleep across species, similarly to that seen with dual orexin receptor antagonism.\n                  <\/jats:p>","DOI":"10.1038\/srep27147","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T05:28:05Z","timestamp":1464931685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man"],"prefix":"10.1038","volume":"6","author":[{"given":"Anthony L.","family":"Gotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Svetnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lai","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Roecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven V.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Garson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge De","family":"Lepeleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Calder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Struyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joseph","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Renger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Winrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"key":"BFsrep27147_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2202-14-90","volume":"14","author":"AL Gotter","year":"2013","unstructured":"Gotter, A. L. et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci. 14, 90 (2013).","journal-title":"BMC Neurosci."},{"key":"BFsrep27147_CR2","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1523\/JNEUROSCI.23-08-03555.2003","volume":"23","author":"JM Zeitzer","year":"2003","unstructured":"Zeitzer, J. M. et al. Circadian and homeostatic regulation of hypocretin in a primate model: Implications for the consolidation of wakefulness. J. Neurosci. 23, 3555\u20133560 (2003).","journal-title":"J. Neurosci."},{"key":"BFsrep27147_CR3","doi-asserted-by":"publisher","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","volume":"96","author":"JJ Hagan","year":"1999","unstructured":"Hagan, J. J. et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA 96, 10911\u201310916 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep27147_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1046\/j.1460-9568.2000.00919.x","volume":"12","author":"DC Piper","year":"2000","unstructured":"Piper, D. C., Upton, N., Smith, M. I. & Hunter, A. J. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. 12, 726\u2013730 (2000).","journal-title":"Eur. J. Neurosci."},{"key":"BFsrep27147_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 355, 39\u201340 (2000).","journal-title":"Lancet."},{"key":"BFsrep27147_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365\u2013376 (1999).","journal-title":"Cell"},{"key":"BFsrep27147_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"BFsrep27147_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","volume":"38","author":"JT Willie","year":"2003","unstructured":"Willie, J. T. et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38, 715\u2013730 (2003).","journal-title":"Neuron"},{"key":"BFsrep27147_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm1544","volume":"13","author":"C Brisbare-Roch","year":"2007","unstructured":"Brisbare-Roch, C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150\u2013155 (2007).","journal-title":"Nat. Med."},{"key":"BFsrep27147_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/clpt.2011.370","volume":"91","author":"P Hoever","year":"2012","unstructured":"Hoever, P. et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin. Pharmacol. Ther. 91, 975\u2013985 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFsrep27147_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.5665\/sleep.1996","volume":"35","author":"P Bettica","year":"2012","unstructured":"Bettica, P. et al. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35, 1097\u20131104 (2012).","journal-title":"Sleep"},{"key":"BFsrep27147_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2014","unstructured":"Herring, W. J. et al. Suvorexant in Patients with Insomnia: Results from Two 3-Month Randomized Controlled Clinical Trials. Biol. Psychiatry. 79, 136\u2013148 (2014).","journal-title":"Biol. Psychiatry."},{"key":"BFsrep27147_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson, D. et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13, 461\u2013471 (2014).","journal-title":"Lancet Neurol."},{"key":"BFsrep27147_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/01677063.2011.566953","volume":"25","author":"CJ Winrow","year":"2011","unstructured":"Winrow, C. J. et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 25, 52\u201361 (2011).","journal-title":"J Neurogenet."},{"key":"BFsrep27147_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2202-15-109","volume":"15","author":"AL Gotter","year":"2014","unstructured":"Gotter, A. L. et al. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC. Neurosci. 15, 109 (2014).","journal-title":"BMC. Neurosci."},{"key":"BFsrep27147_CR16","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/npp.2013.139","volume":"38","author":"SV Fox","year":"2013","unstructured":"Fox, S. V. et al. Quantitative electroencephalography within sleep\/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 38, 2401\u20132408 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"BFsrep27147_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/npp.2011.310","volume":"37","author":"P Bettica","year":"2012","unstructured":"Bettica, P. et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37, 1224\u20131233 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"BFsrep27147_CR18","first-page":"259","volume":"36","author":"H Sun","year":"2013","unstructured":"Sun, H. et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36, 259\u2013267 (2013).","journal-title":"Sleep"},{"key":"BFsrep27147_CR19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring, W. J. et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265\u20132274 (2012).","journal-title":"Neurology"},{"key":"BFsrep27147_CR20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.5665\/sleep.4068","volume":"37","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 37, 1609\u20131619 (2014).","journal-title":"Sleep"},{"key":"BFsrep27147_CR21","first-page":"A91","volume":"23","author":"YY Kisanuki","year":"2000","unstructured":"Kisanuki, Y. Y. et al. The role of orexin receptor type-1 (OX1R) in the regulation of sleep. Sleep 23, A91 (2000).","journal-title":"Sleep"},{"key":"BFsrep27147_CR22","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.5665\/sleep.2232","volume":"35","author":"GM Mang","year":"2012","unstructured":"Mang, G. M. et al. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35, 1625\u20131635 (2012).","journal-title":"Sleep"},{"key":"BFsrep27147_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.109.152009","volume":"330","author":"C Dugovic","year":"2009","unstructured":"Dugovic, C. et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142\u2013151 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFsrep27147_CR24","doi-asserted-by":"publisher","first-page":"e39131","DOI":"10.1371\/journal.pone.0039131","volume":"7","author":"SR Morairty","year":"2012","unstructured":"Morairty, S. R. et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. Plos One 7, e39131 (2012).","journal-title":"Plos One"},{"key":"BFsrep27147_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1460-9568.2010.07401.x","volume":"32","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. Eur. J. Neurosci. 32, 1528\u20131536 (2010).","journal-title":"Eur. J. Neurosci."},{"key":"BFsrep27147_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neuroscience.2014.08.017","volume":"279","author":"RC Choudhary","year":"2014","unstructured":"Choudhary, R. C., Khanday, M. A., Mitra, A. & Mallick, B. N. Perifornical orexinergic neurons modulate REM sleep by influencing locus coeruleus neurons in rats. Neuroscience 279, 33\u201343 (2014).","journal-title":"Neuroscience"},{"key":"BFsrep27147_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnins.2014.00028","volume":"8","author":"C Dugovic","year":"2014","unstructured":"Dugovic, C. et al. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front. Neurosci. 8, 28 (2014).","journal-title":"Front. Neurosci."},{"key":"BFsrep27147_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","volume":"354","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure, P. et al. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J. Pharmacol. Exp. Ther. 354, 471\u2013482 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFsrep27147_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cmdc.201300447","volume":"9","author":"AJ Roecker","year":"2014","unstructured":"Roecker, A. J. et al. Discovery of 5\u2033-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2\u2032:5\u2032, 3\u2033-terpyridine-3\u2032-carbo xamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Chem Med Chem. 9, 311\u2013322 (2014).","journal-title":"Chem Med Chem."},{"key":"BFsrep27147_CR30","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1016\/j.bmcl.2014.08.041","volume":"24","author":"AJ Roecker","year":"2014","unstructured":"Roecker, A. J. et al. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg. Med. Chem. Lett. 24, 4884\u20134890 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFsrep27147_CR31","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1021\/jm4007627","volume":"56","author":"C Betschart","year":"2013","unstructured":"Betschart, C. et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J. Med. Chem. 56, 7590\u20137607 (2013).","journal-title":"J. Med. Chem."},{"key":"BFsrep27147_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0091-3057(76)90298-7","volume":"5","author":"DA Babcock","year":"1976","unstructured":"Babcock, D. A., Narver, E. L., Dement, W. C. & Mitler, M. M. Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol. Biochem. Behav. 5, 599\u2013602 (1976).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"BFsrep27147_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/exnr.1998.6787","volume":"151","author":"MS Reid","year":"1998","unstructured":"Reid, M. S. et al. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp. Neurol. 151, 89\u2013104 (1998).","journal-title":"Exp. Neurol."},{"key":"BFsrep27147_CR34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1177\/0269881111408954","volume":"26","author":"P Bettica","year":"2011","unstructured":"Bettica, P. et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J. Psychopharmacol. 26, 1058\u20131070 (2011).","journal-title":"J. Psychopharmacol."},{"key":"BFsrep27147_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sleep.2015.10.007","volume":"19","author":"E Snyder","year":"2016","unstructured":"Snyder E. et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 19, 93\u2013100 (2016).","journal-title":"Sleep Med."},{"key":"BFsrep27147_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0304-3940(03)00066-1","volume":"341","author":"MI Smith","year":"2003","unstructured":"Smith, M. I., Piper, D. C., Duxon, M. S. & Upton, N. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 341, 256\u2013258 (2003).","journal-title":"Neurosci. Lett."},{"key":"BFsrep27147_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fnins.2013.00230","volume":"7","author":"GE Callander","year":"2013","unstructured":"Callander, G. E. et al. Kinetic properties of \u201cdual\u201d orexin receptor antagonists at OX1R and OX2R orexin receptors. Front. Neurosci. 7, 230 (2013).","journal-title":"Front. Neurosci."},{"key":"BFsrep27147_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fnins.2013.00235","volume":"7","author":"D Hoyer","year":"2013","unstructured":"Hoyer, D. et al. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front. Neurosci. 7, 235 (2013).","journal-title":"Front. Neurosci."},{"key":"BFsrep27147_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fnbeh.2014.00182","volume":"8","author":"PL Tannenbaum","year":"2014","unstructured":"Tannenbaum, P. L. et al. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front. Behav. Neurosci. 8, 182 (2014).","journal-title":"Front. Behav. Neurosci."},{"key":"BFsrep27147_CR40","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","volume":"62","author":"CJ Winrow","year":"2012","unstructured":"Winrow, C. J. et al. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 62, 978\u2013987 (2012).","journal-title":"Neuropharmacology"},{"key":"BFsrep27147_CR41","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"CD Cox","year":"2010","unstructured":"Cox, C. D. et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl] [5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320\u20135332 (2010).","journal-title":"J. Med. Chem."},{"key":"BFsrep27147_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.brainres.2004.02.067","volume":"1010","author":"JJ Renger","year":"2004","unstructured":"Renger, J. J., Dunn, S. L., Motzel, S. L., Johnson, C. & Koblan, K. S. Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res. 1010, 45\u201354 (2004).","journal-title":"Brain Res."},{"key":"BFsrep27147_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0013-4694(85)91073-9","volume":"61","author":"CA Kushida","year":"1985","unstructured":"Kushida, C. A., Baker, T. L. & Dement, W. C. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr. Clin. Neurophysiol. 61, 61\u201370 (1985).","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"BFsrep27147_CR44","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1523\/JNEUROSCI.17-16-06401.1997","volume":"17","author":"S Nishino","year":"1997","unstructured":"Nishino, S. et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J. Neurosci. 17, 6401\u20136408 (1997).","journal-title":"J. Neurosci."},{"key":"BFsrep27147_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/00207459008994241","volume":"52","author":"T Akerstedt","year":"1990","unstructured":"Akerstedt, T. & Gillberg, M. Subjective and objective sleepiness in the active individual. Int. J. Neurosci. 52, 29\u201337 (1990).","journal-title":"Int. J. Neurosci."},{"key":"BFsrep27147_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond, A. & Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 47, 211\u2013218 (1974).","journal-title":"Br. J. Med. Psychol."},{"key":"BFsrep27147_CR47","unstructured":"Rechtschaffen, A. & Kales, A. A. In A Manual of Standardized Terminology, Techniques and scoring system for sleep stages of human subjects, (eds Rechtschaffen, A. & Kales, A. A. ) (Brain Information Service\/Brain Research Institute, University of California, 1968)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep27147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27147","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:30:51Z","timestamp":1672875051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep27147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,28]]}},"alternative-id":["BFsrep27147"],"URL":"https:\/\/doi.org\/10.1038\/srep27147","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,3]]},"assertion":[{"value":"28 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are current or former employees of Merck & Co., Inc., Kenilworth, NJ, known as Merck Sharp & Dohme Corp. (MSD) outside the United States and Canada, have received salary and research support from the company, and may own stock\/stock options in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27147"}}